Identification of immunogenic cell death-associated subtypes and characterization of the tumor microenvironment in endometrial cancer

被引:3
作者
Pan, Fang [1 ]
Luo, Yonghua [2 ]
Wang, Lanyu [3 ]
Cheng, Yulan [4 ]
Bu, Wenxia [4 ]
Zhao, Xinyuan [4 ]
Xu, Yiwen [5 ,8 ]
Chen, Lin [6 ]
Wang, Hongxing [1 ,7 ]
机构
[1] Nantong Univ, Nantong Maternal & Child Hlth Hosp, Nantong, Peoples R China
[2] Nantong Fourth Peoples Hosp, Nantong, Peoples R China
[3] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Urol, Wuxi, Peoples R China
[4] Nantong Univ, Sch Publ Hlth, Dept Occupat Med & Environm Toxicol, Nantong Key Lab Environm Toxicol, Nantong, Peoples R China
[5] Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanjing, Peoples R China
[6] Nantong Univ, Nantong Hosp, Nantong Peoples Hosp Affiliated 3, Nantong Inst Liver Dis, Nantong, Peoples R China
[7] Nantong Univ, Nantong Maternal & Child Hlth Hosp, Nantong 226001, Peoples R China
[8] Nanjing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Nanjing 210029, Peoples R China
关键词
cancer; cervical cell; immunology tumor; immunology; EXPRESSION; SUBSETS; THERAPY; PACKAGE; TRIAL;
D O I
10.1002/jgm.3495
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Immunogenic cell death (ICD) is one of the mechanisms regulating cell death, which activates adaptive immunity in immunocompetent hosts and is associated with tumor progression, prognosis and therapeutic response. Endometrial cancer (EC) is one of the most common malignancies of the female genital tract, and the potential role of immunogenic cell death-related genes (IRGs) in the tumor microenvironment (TME) remains unclear. We describe the variation of IRGs and assess the expression patterns in EC samples from The Cancer Genome Atlas and Gene Expression Omnibus cohorts. Based on the expression of 34 IRGs, we identified two different ICD-related clusters and subsequently differentially expressed genes between the two ICD-related clusters were used for the identification of two ICD gene clusters. We identified the clusters and found that alterations in the multilayer IRG were associated with patient prognosis and TME cell infiltration characteristics. On this basis, ICD score risk scores were calculated, and ICD signatures were constructed and validated for their predictive power in EC patients. To help clinicians better apply the ICD signature, an accurate nomogram was constructed. The low ICD risk group was characterized by high microsatellite instability, high tumor mutational load, high IPS score and stronger immune activation. Our comprehensive analysis of IRGs in EC patients suggested a potential role in the tumor immune interstitial microenvironment, clinicopathological features and prognosis. These findings may improve our understanding of the role of ICDs, and provide a new basis for assessing prognosis and developing more effective immunotherapeutic strategies in EC.
引用
收藏
页数:16
相关论文
共 53 条
  • [1] Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy
    Adkins, Irena
    Fucikova, Jitka
    Garg, Abhishek D.
    Agostinis, Patrizia
    Spisek, Radek
    [J]. ONCOIMMUNOLOGY, 2014, 3 (12): : 1 - 12
  • [2] Nerve Density and Neuronal Biomarkers in Cancer
    Ali, Shahrukh R.
    Jordan, Madeleine
    Nagarajan, Priyadharsini
    Amit, Moran
    [J]. CANCERS, 2022, 14 (19)
  • [3] Unraveling How Obesity Fuels Cancer
    Azvolinsky, Anna
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (04):
  • [4] Dendritic cell subsets and locations
    Balan, Sreekumar
    Saxena, Mansi
    Bhardwaj, Nina
    [J]. IMMUNOBIOLOGY OF DENDRITIC CELLS, PT A, 2019, 348 : 1 - 68
  • [5] Current recommendations and recent progress in endometrial cancer
    Brooks, Rebecca A.
    Fleming, Gini F.
    Lastra, Ricardo R.
    Lee, Nita K.
    Moroney, John W.
    Son, Christina H.
    Tatebe, Ken
    Veneris, Jennifer L.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (04) : 258 - 279
  • [6] Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma
    Cai, Jiayang
    Hu, Yuanyuan
    Ye, Zhang
    Ye, Liguo
    Gao, Lun
    Wang, Yixuan
    Sun, Qian
    Tong, Shiao
    Yang, Ji'an
    Chen, Qianxue
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56
  • [8] Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
    Charoentong, Pornpimol
    Finotello, Francesca
    Angelova, Mihaela
    Mayer, Clemens
    Efremova, Mirjana
    Rieder, Dietmar
    Hackl, Hubert
    Trajanoski, Zlatko
    [J]. CELL REPORTS, 2017, 18 (01): : 248 - 262
  • [9] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
  • [10] Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC
    Chi, Hao
    Xie, Xixi
    Yan, Yingjie
    Peng, Gaoge
    Strohmer, Dorothee Franziska
    Lai, Guichuan
    Zhao, Songyun
    Xia, Zhijia
    Tian, Gang
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13